Cardiol Therapeutics saw a significant drop in its stock price, raising concerns among investors.
Yesterday, Cardiol Therapeutics Inc Class A (CRDL.TO) experienced a notable decline, with its stock price falling by 6.74% to close at CA$2.49. This downturn has left investors questioning the stability and future prospects of the company, especially given its recent achievements in clinical trials.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$302.57M
52W high
$3.23
52W low
$1.23
1W change
-4.96%
Beta
0.61
Analyst Price Targets
Based on analyst covering CRDL · as of Sep 17, 2026
Wall Street analysts forecast CRDL stock price to rise 239.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+239.0% Upside
Current Price
C$1.77
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
81.8%
Annualized
90-Day Vol
63.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.98
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$2.64 | C$1.99 – C$3.50 |
| 60 trading days | C$2.80 | C$1.88 – C$4.18 |
| 90 trading days | C$2.98 | C$1.83 – C$4.85 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious, as the stock's recent performance may indicate underlying challenges despite positive developments in clinical trials.
6.74% Drop in Stock Price
Cardiol Therapeutics' stock fell to CA$2.49, reflecting investor concerns despite recent clinical milestones.
Bull case
The company recently hit its Phase III MAVERIC enrollment target ahead of schedule, which could boost investor confidence in its clinical pipeline.
Bear case
The sharp decline in stock price suggests that market sentiment may be turning negative, potentially overshadowing recent positive news.
Advertisement
Recent Achievements Overshadowed
Despite the stock's decline, Cardiol Therapeutics has made significant strides in its clinical trials. The company recently announced it achieved its Phase III MAVERIC enrollment target ahead of schedule. This trial aims to assess how well CardiolRx™ can reduce recurrence risk in patients with recurrent pericarditis, with topline results expected in mid-2027. However, the market's reaction suggests that investors may be skeptical about the company's ability to turn these achievements into financial success.
Market Sentiment and Future Outlook
The 6.74% drop in Cardiol's stock price indicates a shift in market sentiment. Investors may be reacting to broader market trends or concerns about the company's financial health, given its current market cap of CA$302.57 million and lack of profitability. As Cardiol continues to navigate its clinical trials and seeks to raise capital, the stock's volatility could persist, making it essential for investors to stay informed about upcoming developments and market conditions.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
